褪黑素失调、睡眠障碍与脓毒症相关谵妄的关联:一项中介分析的前瞻性队列研究
该前瞻性队列纳入99例脓毒症患者,用RCSQ评估睡眠质量并测褪黑素浓度,经多因素logistic、PSM、IPW、混合效应及贝叶斯和中介分析校正混杂。睡眠障碍先于SAD发生且呈持续时间依赖效应(P<0.001),与谵妄风险升高1.45-7.69倍相关(P<0.05);褪黑素越低多维睡眠损害越重(β=7.65-13.10),SAD患者呈双相褪黑素抑制。中介分析示睡眠障碍起病时褪黑素中介效应ADE=0.60(P<0.001),ACME=-0.110(P=0.024)。提示褪黑素可能是连接睡眠障碍与SAD的生物学候选通路,需进一步研究证实。
要点
- 脓毒症患者睡眠障碍先于SAD发生,呈持续时间依赖效应(P<0.001),多因素logistic、PSM、IPW及贝叶斯分析均显示谵妄风险升高1.45-7.69倍(P<0.05)。
- 褪黑素浓度越低,多维睡眠损害越重(β=7.65-13.10,均P<0.05),尤其睡眠连续性问题(β=9.81)和总体睡眠质量差(β=13.10)。
- SAD患者呈双相褪黑素抑制:睡眠障碍起病时先下降(P<0.001),活动性谵妄发作期进一步降低(P<0.005),且独立于镇静暴露(P>0.05)。
- 睡眠障碍起病时测得的褪黑素中介效应ADE=0.60(P<0.001),睡眠障碍伴随的褪黑素下降与SAD发生相关(ACME=-0.110,P=0.024)。
- 结论为初步证据,作者指出其他因素可能影响该关系,需进一步研究确认,尚不能据此确立因果或改变常规补充褪黑素的实践。
适用人群与场景
- ICU收治的脓毒症患者,前瞻性纵向评估99例;原文未提及具体纳入与排除标准、急诊或院前场景及病情阶段细节。
诊断标准与关键阈值
- 睡眠质量采用Richards-Campbell睡眠问卷(RCSQ)评估,并测定褪黑素浓度;原文未提及RCSQ具体界值或SAD诊断工具名称及阈值。
处置流程与药物剂量
- 原文未提及具体治疗或药物剂量方案;仅报告褪黑素浓度、镇静暴露(P>0.05)与睡眠障碍、SAD的观察性关联。
红旗征与不能漏的情况
- 睡眠障碍先于SAD发生且呈持续时间依赖效应,睡眠障碍持续越久谵妄风险越高(风险升高1.45-7.69倍,P<0.05),需警惕并及时评估睡眠与谵妄状态。
研究设计与关键结果
- 研究类型为前瞻性队列研究,单中心(原文未明确中心数),样本量99例脓毒症患者,无干预对照分组。
- 主要发现:睡眠障碍先于SAD发生,呈持续时间依赖效应(P<0.001),与谵妄风险升高1.45-7.69倍相关(P<0.05),在多因素logistic、PSM、IPW和贝叶斯分析中一致。
- 褪黑素越低与多维睡眠损害越重相关(β=7.65-13.10,均P<0.05),尤其睡眠连续性(β=9.81)和总体睡眠质量(β=13.10)。
- SAD患者呈双相褪黑素抑制:睡眠障碍起病时先下降(P<0.001),活动性谵妄期进一步降低(P<0.005),独立于镇静暴露(P>0.05)。
- 中介分析:睡眠障碍起病时褪黑素ADE=0.60(P<0.001);褪黑素下降与SAD发生的ACME=-0.110(P=0.024)。
证据类型、等级与局限
- 证据类型为前瞻性队列研究,原文未给出证据等级或推荐强度;局限包括单中心、样本量99例、观察性设计不能确立因果,作者明确称结果为初步证据、需进一步研究确认。
对床旁实践的改变
- 支持在ICU脓毒症患者中关注睡眠障碍的持续时间和褪黑素水平变化,将其作为SAD风险的观察指标;但原文为初步观察性证据,未提供补充褪黑素或睡眠干预的剂量方案,不能据此改变常规治疗。
- 常见陷阱:不能把褪黑素下降与SAD的关联当作因果或治疗指征;镇静暴露虽与褪黑素变化无关(P>0.05),但原文未提供镇静药物剂量或方案细节。
指南或共识出处
- 原文未提及指南或共识出处;来源为PubMed收录的Neurocrit Care期刊论文。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis-associated delirium (SAD) is a life-threatening complication in the intensive care unit (ICU). Although sleep disturbances are common in sepsis, their relationship with SAD remains poorly understood. We investigated the link between sleep disturbances, melatonin dysregulation, and SAD.
METHODS: In this prospective cohort study, we longitudinally assessed 99 patients with sepsis. Sleep quality was evaluated using the Richards-Campbell Sleep Questionnaire (RCSQ) and melatonin concentration, and multivariable logistic analysis, propensity score matching (PSM), inverse probability weighting (IPW), mixed-effects models, Bayesian, and mediation analysis to adjust for confounding factors to evaluate the relationship of melatonin with sleep disorder and SAD.
RESULTS: Sleep disorders preceded SAD onset with a duration-dependent effect (P < 0.001) and were associated with a 1.45-7.69-fold higher risk of delirium (P < 0.05) across multivariable logistic analysis, PSM, IPW and Bayesian analysis. Lower melatonin concentrations were correlated with worse multidimensional sleep impairment (β = 7.65-13.10, all P < 0.05), particularly impaired sleep continuity (β = 9.81) and poorer overall sleep quality (β = 13.10). Patients with SAD exhibited biphasic melatonin suppression: initial decline coinciding with sleep disturbances (P < 0.001), followed by further reduction during active delirium episodes (P < 0.005), independent of sedation exposure (P > 0.05). Mediation analysis demonstrated substantial mediating effects of melatonin concentrations measured at sleep disturbance onset (ADE = 0.60, P < 0.001), and melatonin reduction occurring alongside sleep disturbances was associated with SAD development [average causal mediation effects (ACME) = - 0.110, P = 0.024].
CONCLUSIONS: This study provides preliminary evidence that disrupted sleep patterns and altered melatonin secretion may contribute to the development of SAD in ICU patients. While our findings support melatonin not only as a risk factor for sleep disruption and SAD, but also as a biologically plausible candidate linking sleep disruption to SAD, the potential influence of other factors underscores the need for further research to confirm this relationship.
参考来源
- Zhao L, Cui Q, Dong S, et al. Association Among Melatonin Dysregulation, Sleep Disorders, and Sepsis-Associated Delirium: A Prospective Cohort Study with Mediation Analysis. Neurocrit Care. 2026. PMID: 42469580. doi:10.1007/s12028-026-02594-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。